The global demand for plasmid DNA has risen dramatically in the recent years, largely driven by the unprecedented growth in cell and gene therapy. The success in these therapies has increased demand for plasmid DNA used to produce viral vectors, both in quantities for commercial products, as well as for early development programs. In addition, the current situation with COVID-19 has further increased the demand for adenovirus-based or mRNA vaccines, for which pDNA is also the starting material. Unfortunately, scaling up manufacturing capacity for pDNA is complicated and has become a bottleneck for the industry. Plasmid DNA manufacturers that are looking for ways to accelerate production and confirm high quality product are encouraged to sign up for this webinar. We will share a platform process that will eliminate sample dilution and accurately measure DNA purity ratios in less than 5 minutes with an Rvalue accuracy of less than 2% deviation for all 25 sampling percentages. Slope spectroscopy has proven to be a critical analytical method, expediting the testing of challenging samples, providing immediate feedback, and opening up multiple possibilities for meeting your process needs.